LINK‑A lncRNA participates in the pathogenesis of glioma by interacting with survivin

Hua,Xia; Li,Guangxing; Liu,Zhongtao; Niu,Zhanfeng

doi:10.3892/etm.2019.7716

LINK‑A lncRNA participates in the pathogenesis of glioma by interacting with survivin

Authors:
- Xia Hua
- Guangxing Li
- Zhongtao Liu
- Zhanfeng Niu
View Affiliations

Affiliations: Department of Neurosurgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750003, P.R. China
Published online on: July 1, 2019 https://doi.org/10.3892/etm.2019.7716
Pages: 1581-1586
Copyright: © Hua et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long intergenic non‑coding RNA for kinase activation (LINK‑A) long non‑coding RNA (lncRNA) has been characterized in triple negative breast cancer, but its potential involvement in glioma has not been investigated. In the present study, serum levels of LINK‑A lncRNA and survivin in patients with glioma and healthy controls were determined by RT‑qPCR and ELISA, respectively. The diagnostic value of serum LINK‑A lncRNA for glioma was evaluated by receiver operating characteristic (ROC) curve analysis. Potential correlations between serum levels of LINK‑A lncRNA and survivin were analyzed by Pearson correlation coefficient. LINK‑A lncRNA siRNA, LINK‑A lncRNA‑carrying expression vector and survivin‑carrying expression vector were transfected into glioma cells, and the effects on LINK‑A lncRNA expression, survivin expression and cell apoptosis were explored by RT‑qPCR, western blot analysis and annexin V/propidium iodide staining. It was observed that the serum levels of LINK‑A lncRNA and survivin were significantly higher in patients with glioma compared with healthy controls. Increased levels of LINK‑A lncRNA distinguished glioma patients from healthy controls, based on ROC curve analysis. Serum levels of LINK‑A lncRNA and survivin were positively correlated in glioma patients, but not in healthy controls. Overexpression of LINK‑A lncRNA led to increased survivin protein expression, while survivin overexpression had no effect on LINK‑A lncRNA expression. LINK‑A lncRNA and survivin overexpression each reduced glioma cell apoptosis, but LINK‑A lncRNA siRNA‑mediated knockdown increased apoptosis. Survivin overexpression attenuated the inducing effects of LINK‑A lncRNA knockdown on apoptosis. In conclusion, LINK‑A lncRNA inhibited glioma cell apoptosis potentially by the upregulation of survivin. The present study revealed that LINK‑A may serve as possible diagnostic marker for glioma.

View Figures

View References

1	Goodenberger ML and Jenkins RB: Genetics of adult glioma. Cancer Genet. 205:613–621. 2012. View Article : Google Scholar : PubMed/NCBI
2	Mamelak AN and Jacoby DB: Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv. 4:175–186. 2007. View Article : Google Scholar : PubMed/NCBI
3	Macartney G, Harrison MB, VanDenKerkhof E, Stacey D and McCarthy P: Quality of life and symptoms in pediatric brain tumor survivors: A systematic review. J Pediatr Oncol Nurs. 31:65–77. 2014. View Article : Google Scholar : PubMed/NCBI
4	Rice T, Lachance DH, Molinaro AM, Eckel-Passow JE, Walsh KM, Barnholtz-Sloan J, Ostrom QT, Francis SS, Wiemels J, Jenkins RB, et al: Understanding inherited genetic risk of adult glioma-a review. Neurooncol Pract. 3:10–16. 2016.PubMed/NCBI
5	Radner H, el-Shabrawi Y, Eibl RH, Brüstle O, Kenner L, Kleihues P and Wiestler OD: Tumor induction by ras and myc oncogenes in fetal and neonatal brain: Modulating effects of developmental stage and retroviral dose. Acta Neuropathol. 86:456–465. 1993. View Article : Google Scholar : PubMed/NCBI
6	Sah NK, Khan Z, Khan GJ and Bisen PS: Structural, functional and therapeutic biology of survivin. Cancer Lett. 244:164–171. 2006. View Article : Google Scholar : PubMed/NCBI
7	Jaiswal PK, Goel A and Mittal RD: Survivin: A molecular biomarker in cancer. Indian J Med Res. 141:389–397. 2015. View Article : Google Scholar : PubMed/NCBI
8	Chen X, Duan N, Zhang C and Zhang W: Survivin and tumorigenesis: Molecular mechanisms and therapeutic strategies. J Cancer. 7:314–323. 2016. View Article : Google Scholar : PubMed/NCBI
9	Garg H, Suri P, Gupta JC, Talwar GP and Dubey S: Survivin: A unique target for tumor therapy. Cancer Cell Int. 16:492016. View Article : Google Scholar : PubMed/NCBI
10	Mobahat M, Narendran A and Riabowol K: Survivin as a preferential target for cancer therapy. Int J Mol Sci. 15:2494–2516. 2014. View Article : Google Scholar : PubMed/NCBI
11	Chen H, Yang F, Li X, Gong ZJ and Wang LW: Long noncoding RNA LNC473 inhibits the ubiquitination of survivin via association with USP9X and enhances cell proliferation and invasion in hepatocellular carcinoma cells. Biochem Biophys Res Commun. 499:702–710. 2018. View Article : Google Scholar : PubMed/NCBI
12	Yang R, Qu S, Liang H, Chen X, Zhang C and Guo H: Long noncoding RNA H19 regulates survivin expression in bladder cancer as sponge of miR-138-5p. Eur Urol Suppl. 16:e1464–e1465. 2017. View Article : Google Scholar
13	Lin A, Li C, Xing Z, Hu Q, Liang K, Han L, Wang C, Hawke DH, Wang S, Zhang Y, et al: The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer. Nat Cell Biol. 18:213–224. 2016. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Zhang F, Chu J and Wang F: Expression and clinical significance of cyclooxygenase 2 and survivin in human gliomas. Oncol Lett. 14:1303–1308. 2017. View Article : Google Scholar : PubMed/NCBI
16	Lv S, Dai C, Liu Y, Shi R, Tang Z, Han M, Bian R, Sun B and Wang R: Retraction note to: The impact of survivin on prognosis and clinicopathology of glioma patients: A systematic meta-analysis. Mol Neurobiol. 54:23762017. View Article : Google Scholar : PubMed/NCBI
17	Jane EP, Premkumar DR, Sutera PA, Cavaleri JM and Pollack IF: Survivin inhibitor YM155 induces mitochondrial dysfunction, autophagy, DNA damage and apoptosis in Bcl-xL silenced glioma cell lines. Mol Carcinog. 56:1251–1265. 2017. View Article : Google Scholar : PubMed/NCBI
18	Zhang X, Sun S, Pu JK, Tsang AC, Lee D, Man VO, Lui WM, Wong ST and Leung GK: Long non-coding RNA expression profiles predict clinical phenotypes in glioma. Neurobiol Dis. 48:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
19	Wang P, Ren Z and Sun P: Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation. J Cell Biochem. 113:1868–1874. 2012. View Article : Google Scholar : PubMed/NCBI
20	Zhang H, Wei DL, Wan L, Yan SF and Sun YH: Highly expressed lncRNA CCND2-AS1 promotes glioma cell proliferation through Wnt/β-catenin signaling. Biochem Biophys Res Commun. 482:1219–1225. 2017. View Article : Google Scholar : PubMed/NCBI
21	Liao Y, Shen L, Zhao H, Liu Q, Fu J, Guo Y, Peng R and Cheng L: LncRNA CASC2 interacts with miR-181a to modulate glioma growth and resistance to TMZ through PTEN pathway. J Cell Biochem. 118:1889–1899. 2017. View Article : Google Scholar : PubMed/NCBI
22	Lin A, Hu Q, Li C, Xing Z, Ma G, Wang C, Li J, Ye Y, Yao J, Liang K, et al: The LINK-A lncRNA interacts with PtdIns(3,4,5)P₃ to hyperactivate AKT and confer resistance to AKT inhibitors. Nat Cell Biol. 19:238–251. 2017. View Article : Google Scholar : PubMed/NCBI
23	Kopreski MS, Benko FA, Kwak LW and Gocke CD: Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res. 5:1961–1965. 1999.PubMed/NCBI